カテゴリ： GlobalData, インド, 企業調査

Lupin Ltd (LUPIN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Lupin Ltd (LUPIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10042
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：97
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：インド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Lupin Ltd (Lupin) focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB and cephalosporins. It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. Lupin develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries has manufacturing facilities in India, the US, Japan, Mexico and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.

Lupin Ltd (LUPIN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lupin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Lupin Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lupin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Lupin Ltd, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Kyowa Pharma to Acquire 21 Products from Shionogi 15
Lupin to Acquire Product Portfolio from Temmler Pharma 16
Lupin Plans To Acquire US Branded Drugs 17
Venture Financing 18
Symbiomix Therapeutics Raises USD6 Million in Venture Financing 18
Symbiomix Therapeutics Raises USD41 Million in Series A Financing 19
Symbiomix Therapeutics Raises USD20 Million in Venture Financing 20
Private Equity 21
Bayer May Sell Dermatology Business 21
Partnerships 22
Lupin and Mylan Enter into Partnership Agreement 22
Lupin and Nichi-Iko Enter into Partnership Agreement 23
Lupin, CSIR-National Chemical Laboratory and DST Enter into Research Agreement 24
Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 25
Boehringer Ingelheim Expands Co-Marketing Agreement with Lupin 26
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 27
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 28
Lupin Enters into Development Agreement with Celon for Generic Advair Diskus 29
Lupin Enters into Co-Development Agreement with Merck Serono 30
Lupin Enters into Distribution Agreement with Salix Pharma 31
Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 32
Lupin Enters Into Joint Venture Agreement With Yoshindo To Form YL Biologics 33
Gavis Pharma Partners with Modavar Pharma 34
Lupin Enters Into Co-Promotion Agreement With Onset Dermatologics For Locoid Lotion 35
Licensing Agreements 36
Lupin Enters into Licensing Agreement with Eli Lilly and Company 36
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 37
Lupin Enters into Licensing Agreement with Medicines Patent Pool 38
Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 39
Merck Enters Into Licensing Agreement With Lupin 40
Equity Offering 41
Lupin Plans to Raise USD1.2 Billion in Public Offering of Equity Securities 41
Asset Transactions 42
G&W Labs to Acquire Two Generic Drugs of Gavis Pharma from Lupin 42
Lupin to Acquire Product Portfolio from Temmler Pharma 43
Acquisition 44
Lupin Pharma Acquires Symbiomix Therapeutics 44
Lupin Acquires GAVIS Pharma for USD880 Million 45
Lupin Acquires Biocom 46
Lupin Acquires Medquimica 47
Lupin to Acquire Remaining 40% Stake in Pharma Dynamics 48
Lupin Acquires Labs Grin, Ophthalmology Therapies Provider 49
Lupin Plans to Acquire Generics Manufacturing Companies In Europe for up to USD1 Billion 50
Lupin Acquires Nanomi 51
Gavis Pharma Revises Open Offer Price To Acquire Additional 26% Stake In Wintac For US$5 Million 52
Aenova Completes Acquisition Of Temmler Pharma, Contract Manufacturing Company 53
Lupin Ltd – Key Competitors 54
Lupin Ltd – Key Employees 55
Lupin Ltd – Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Joint Venture 60
Recent Developments 61
Strategy And Business Planning 61
May 09, 2017: Lupin Announces Opening of its new 100,000 square foot expansion at its Somerset, NJ Manufacturing Site 61
Financial Announcements 62
Oct 31, 2018: Lupin quarter II, FY2019 – results 62
Aug 08, 2018: LUPIN: Quarter I, FY2019 -results 64
May 15, 2018: Lupin announces fiscal year 2018 Results, Board recommends dividend of 250% 66
Feb 06, 2018: Lupin Quarter III, FY2018-Results 68
Oct 30, 2017: Lupin Quarter II, FY2018 – Results 70
May 24, 2017: Lupin Announces Quarter IV and Annual Results, FY2017 72
Feb 09, 2017: Lupin Quarter III Results, FY2017 74
Corporate Communications 76
Sep 18, 2018: Lupin appoints Alok Sonig as CEO – US Generics and Global Head – Generics R&D & Biosimilars 76
May 31, 2018: Lupin appoints Nicholas Hart as President – Specialty for US Business 77
Sep 18, 2017: Lupin appoints Jim Loerop as Chief Corporate Development Officer 78
Legal and Regulatory 79
Oct 19, 2018: Lupin’s Pithampur unit-3 (Indore) inspected by US FDA 79
Sep 14, 2018: Lupin’s Nagpur facility inspection by US FDA concluded with no observation 80
Sep 04, 2018: Lupin’s Tarapur API Manufacturing Facility Inspected by US FDA 81
Aug 24, 2018: Lupin’s Nagpur facility receives Establishment Inspection Report from US FDA 82
Jul 30, 2018: Lupin’s mandideep facility gets approval from EDQM 83
Jul 16, 2018: Lupin’s Goa facility gets approval from UK MHRA 84
May 14, 2018: Lupin’s Nagpur facility US FDA inspection concluded with no observations 85
Apr 06, 2018: Lupin’s Pithampur Unit 1 facility receives Establishment Investigation report (EIR) from US FDA 86
Apr 03, 2018: Lupin’s Goa facility completes successful UK MHRA inspection 87
Apr 02, 2018: Lupin’s Pithampur Unit cleared by Health Canada 88
Aug 21, 2017: Lupin receives EIR from US FDA for Aurangabad, April 2017 Inspection 89
Jul 31, 2017: Lupin’s Aurangabad facility inspection concluded by US FDA 90
Jul 28, 2017: Lupin’s Pithampur facility inspection concluded by US FDA without any observations 91
Government and Public Interest 92
Jun 29, 2018: Lupin announces tie-up with European Association of Urology (EAU) 92
Product News 93
05/27/2017: Lupin Pharmaceuticals Announces a Nationwide Recall of Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol 1mg/0.02mg Chewable Tablets and Ferrous Fumarate 75mg) Tablets 93
May 10, 2018: Lupin launches Corcal Bone and Beauty supplement 94
03/16/2017: Lupin launches Generic Minastrin 24 Fe chewable tablets in the US 95
Other Significant Developments 96
Jul 21, 2017: Lupin’s Goa facility inspection concluded by US FDA without any observations 96
Appendix 97
Methodology 97
About GlobalData 97
Contact Us 97
Disclaimer 97

List of Tables
Lupin Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lupin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lupin Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Lupin Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lupin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Kyowa Pharma to Acquire 21 Products from Shionogi 15
Lupin to Acquire Product Portfolio from Temmler Pharma 16
Lupin Plans To Acquire US Branded Drugs 17
Symbiomix Therapeutics Raises USD6 Million in Venture Financing 18
Symbiomix Therapeutics Raises USD41 Million in Series A Financing 19
Symbiomix Therapeutics Raises USD20 Million in Venture Financing 20
Bayer May Sell Dermatology Business 21
Lupin and Mylan Enter into Partnership Agreement 22
Lupin and Nichi-Iko Enter into Partnership Agreement 23
Lupin, CSIR-National Chemical Laboratory and DST Enter into Research Agreement 24
Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 25
Boehringer Ingelheim Expands Co-Marketing Agreement with Lupin 26
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 27
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 28
Lupin Enters into Development Agreement with Celon for Generic Advair Diskus 29
Lupin Enters into Co-Development Agreement with Merck Serono 30
Lupin Enters into Distribution Agreement with Salix Pharma 31
Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 32
Lupin Enters Into Joint Venture Agreement With Yoshindo To Form YL Biologics 33
Gavis Pharma Partners with Modavar Pharma 34
Lupin Enters Into Co-Promotion Agreement With Onset Dermatologics For Locoid Lotion 35
Lupin Enters into Licensing Agreement with Eli Lilly and Company 36
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 37
Lupin Enters into Licensing Agreement with Medicines Patent Pool 38
Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 39
Merck Enters Into Licensing Agreement With Lupin 40
Lupin Plans to Raise USD1.2 Billion in Public Offering of Equity Securities 41
G&W Labs to Acquire Two Generic Drugs of Gavis Pharma from Lupin 42
Lupin to Acquire Product Portfolio from Temmler Pharma 43
Lupin Pharma Acquires Symbiomix Therapeutics 44
Lupin Acquires GAVIS Pharma for USD880 Million 45
Lupin Acquires Biocom 46
Lupin Acquires Medquimica 47
Lupin to Acquire Remaining 40% Stake in Pharma Dynamics 48
Lupin Acquires Labs Grin, Ophthalmology Therapies Provider 49
Lupin Plans to Acquire Generics Manufacturing Companies In Europe for up to USD1 Billion 50
Lupin Acquires Nanomi 51
Gavis Pharma Revises Open Offer Price To Acquire Additional 26% Stake In Wintac For US$5 Million 52
Aenova Completes Acquisition Of Temmler Pharma, Contract Manufacturing Company 53
Lupin Ltd, Key Competitors 54
Lupin Ltd, Key Employees 55
Lupin Ltd, Other Locations 57
Lupin Ltd, Subsidiaries 57
Lupin Ltd, Joint Venture 60

List of Figures
Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Lupin Ltd, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Lupin Ltd (LUPIN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Veracyte Inc (VCYT)：企業の財務・戦略的SWOT分析
    Summary Veracyte Inc (Veracyte) is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The company’s pipeline products include Afirma thyroid FNA analysis for the diagnosis of thyroid cancer based on its proprietary afirma gene expression classifier. It also …
  • Oramed Pharmaceuticals Inc (ORMP)：企業の財務・戦略的SWOT分析
    Oramed Pharmaceuticals Inc (ORMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • ABC arbitrage SA (ABCA)：企業の財務・戦略的SWOT分析
    ABC arbitrage SA (ABCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Velatia SL：企業の戦略的SWOT分析
    Velatia SL - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Hansen Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Hansen Medical Inc (Hansen Medical), formerly Autocath Inc, a subsidiary of Auris Health Inc, is a medical device company that develops, manufactures and markets magellan robotic system for peripheral vascular intervention. The company’s products comprise robotic system, robotic catheters, s …
  • LifeLabs Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary LifeLabsInc (LifeLabs), formerly MDS Diagnostic Services is a laboratory service provider that diagnoses, treats, monitors and prevent diseases in patients. The laboratory's services include clinical studies and services, drug and alcohol screening, employee wellness, hospital lab services, …
  • Centre for Drug Research and Development-製薬・医療分野：企業M&A・提携分析
    Summary Centre for Drug Research and Development (CDRD) is a drug development and commercialization center that provides infrastructure to transform basic health research in academic institutions and early-stage therapeutic technologies into new medicines. The center offers target validation, screen …
  • Tradewinds Corporation Berhad：企業の戦略・SWOT・財務情報
    Tradewinds Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary Tradewinds Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Ross Stores Inc：戦略・SWOT・企業財務分析
    Ross Stores Inc - Strategy, SWOT and Corporate Finance Report Summary Ross Stores Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Publix Super Markets, Inc.：企業の戦略・SWOT・財務分析
    Publix Super Markets, Inc. - Strategy, SWOT and Corporate Finance Report Summary Publix Super Markets, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • The Warehouse Group Ltd (WHS)：企業の財務・戦略的SWOT分析
    The Warehouse Group Ltd (WHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Volvo Car Corporation：企業の戦略・SWOT・財務分析
    Volvo Car Corporation - Strategy, SWOT and Corporate Finance Report Summary Volvo Car Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Otis Elevator Co：企業の戦略・SWOT・財務情報
    Otis Elevator Co - Strategy, SWOT and Corporate Finance Report Summary Otis Elevator Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Battalion Oil Corp (HKRSQ)：企業の財務・戦略的SWOT分析
    Summary Battalion Oil Corp (Battalion Oil), formerly Halcon Resources Corp, is an independent energy company that carries out the acquisition, production, exploration and development of onshore oil and natural gas properties. Battalion Oil mainly focuses on the Delaware Basin, East Texas. The compan …
  • BNC Bancorp：企業のM&A・事業提携・投資動向
    BNC Bancorp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BNC Bancorp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Intra Energy Corporation Ltd (IEC)：企業の財務・戦略的SWOT分析
    Intra Energy Corporation Ltd (IEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Workspace Group Plc：企業の戦略・SWOT・財務情報
    Workspace Group Plc - Strategy, SWOT and Corporate Finance Report Summary Workspace Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • OncoTartis Inc-製薬・医療分野：企業M&A・提携分析
    Summary OncoTartis Inc (OncoTartis) is a biotechnology company with a focus on development of various treatments for various types of cancers. Its lead candidate OT-82, an orally available NicotinAMide Phosphoribosyl Transferase inhibitor, is being developed for treating broad range of leukemias and …
  • Ashok Leyland Limited：企業の戦略・SWOT・財務情報
    Ashok Leyland Limited - Strategy, SWOT and Corporate Finance Report Summary Ashok Leyland Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Delcath Systems Inc (DCTH)：医療機器：M&Aディール及び事業提携情報
    Summary Delcath Systems Inc (Delcath) specializes in developing percutaneous perfusion technologies to treat primary and metastatic liver cancers. Its patented drug delivery platform delivers ultra-high doses of anti-cancer drugs to the liver, while preventing them from entering the patient's bloods …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆